Skip to main content
JBIO $15.31 +1.66%
JBIO logo
JBIO · Jade Biosciences, Inc.
Track JBIO — free
$15.31 +0.25 (+1.66%) At close · Nov 20
Market Cap
$1.06B
Shares
69.19M
Volume · Nov 20 1.02M Avg daily vol (3M) 911.9K
All webcasts

Conference · 2026-11-11

Jade Biosciences, Inc. (JBIO) November 11, 2026 Conference Transcript

Concluded Nov 11, 2026 Audio replay
Nov 11, 2026 29:20 40 turns
Period
2026-11-11
Runtime
29:20
Sources
2 artifacts

Transcript & audio

29:20 Audio
Alex Thomas Analyst — Stiefel

Good morning, everyone. I'm Alex Thomas, a biotech analyst here at Stiefel. Very happy to have Jade Biosciences joining us this morning, CFO Brad Doms, and CMO Ed Connor. Maybe we can get over to Brad for a quick overview of Jade, and then we'll get into a Q&A. So, Brad, over to you.

Great. Yeah, thanks a lot, Alex, and thanks to CFL for hosting us at this conference. It's really great to be here. So Jade Biosciences, we are a company that was founded in 2024 with monoclonal antibodies focused on autoimmune diseases. We were the fourth spin-out of Paragon. So Paragon now, I think, is nine companies, if memory serves, although I've admittedly lost count. But yeah, Apogee, Aruca, and then Spire, and then Jade was spun out, again, to focus on autoimmune diseases. We have rights to three assets. Our lead program is Jade 101, which is an anti-April monoclonal antibody being initially developed for the treatment of IGA nephropathy with the potential to expand indications. Jade 101 was designed to really address two key challenges we had observed in the space. So one was binding affinity. Jade 101 is a femtomolar binder to April, and we think the potency really matters to get really deep and durable IGA reductions, which can have a So there's a lot of YTE modification in the FC for an extended half-life. We can get to our Phase I data later, but we think that both of those two features are manifesting themselves in the clinic so far and give us confidence as we move forward. We initiated a Phase II in May. Soon thereafter, we announced our positive Phase I results in June. We'll have the Phase II interim results in the second quarter of 2027. We'll be focused on UPCR, among other things that we can talk about. Our phase three is expected to initiate this quarter as well, so we're moving at a very rapid clip. I would say priority number one is getting this drug to the market as quickly as possible. It's a very exciting opportunity in IGAM, which we estimate is a $20 billion market in the U.S. alone. Jade 201 is our second program. It's our afucosylated anti-BAF-R monoclonal antibody initially being developed in RA, where We have a phase one ongoing that was initiated in May. We'll have data in 2027 for that program, after which we will declare our lead indication or indications when I have a very focused development strategy there, because there's obviously a lot of places you can take a BAF-R. And then our third program is Jade 301. It's an anti-interferon beta monoclonal antibody for the treatment initially of dermatomyositis, which is a very exciting indication, and that's really leveraging some of the Pfizer data that we've seen, which had Best in Disease Total Improvement Score and Best in Disease C-DASI. We're starting in sub-Q, whereas that drug is IV. We've also shown an extended half-life there. And then from a capital standpoint, $461 million as of June 30th. We'll report earnings the next couple days here. We'll provide an update, but run way into the fourth quarter of 2020. So feeling very well capitalized to execute on all these programs and excited about three catalysts next year.

Alex Thomas Analyst — Stiefel

Yeah, great. Great. And, you know, obviously, ASN recently happened. A lot of focus on IG nephropathy, in particular, with a bunch of phase three data sets for the first gen bath April class. I wonder if we could sort of walk through some of the key takeaways from ASN and sort of where that sort of leaves the IGAN space today.

Yeah, I think the key takeaway is, again, you're seeing stability EGFR over two years. I think some of the key data points that we saw, particularly on cibaprenilumab, they did a... Outcomes measure, looking at renal outcomes, which was either dialysis or 30% or greater reduction in kidney function, which is a large metric, and showed a 97% reduction, and that's very key. Both, obviously, from a patient standpoint, because that significant amount of kidney loss puts you well on your way to eventually needing dialysis, but very much from a health economic outcome, which is obviously the... It's important from a pair perspective as well. The other piece of SIBI data that didn't maybe get as much attention but I think is equally important is if you look at their IGG curve over time, there was some talk that maybe there was some slight decline but at the two-year mark very much stable to actually even coming So they've seen it in that 30 to 35% drop range. They haven't seen any evidence of hypogammaglobulinemia, which is also important from a safety perspective.

Alex Thomas Analyst — Stiefel

I guess maybe one of the debates, historically, is whether or not having BAF plus April actually matters. I guess at this point... Have we definitively answered that question? Does BAF matter?

Yeah, it's interesting. I mean, there's obviously competitors that make a claim that it matters. We just look at the clinical data, right? I think if you do the cross-trial comparisons, there's three phase threes that I have read out so far. You see we can just run through them in order, right? So Sibipremimab, as Ed was mentioning, that is the selective anti-April. It had a 51% placebo-adjusted proteinuria with EGFR stabilization, a tassicep that's the dual April Baff that's being developed by Vera, which was approved in July as TruTacna, had about a 42-ish percent placebo-adjusted proteinuria, again, with EGFR stabilization, and then povetassicep, the Vertex drug, which is also a dual April Baff tassifusion, had a 49.8% placebo-adjusted reduction, So they're all very effective, and it's a plasma cell-mediated disease. So scientifically, you kind of take a step back, you really shouldn't need BAF to add anything on the efficacy side, and I think that's now been proven out in clinical trials. The one that kind of flies under the radar, not to disparage my colleagues, many of whom came from Chinook Therapeutics, but Zyga-Kybar, which is being developed by Novartis, we've now seen data on phase two going out to something like 150 weeks, And you see really good proteinuria reductions, and they continue to get reduced over time. The challenge with that drug, obviously, is that it's 200, 300 milligram doses every two weeks from a convenience standpoint. We think that'll be challenging. But if you look across the space, it's really hard to make an argument that anything in the data is pointing to BAF, adding anything. And our point would be to the contrary, that it's really, because it's unnecessary to hit this broader compartment of B cells, IGAM patients, they're diagnosed in their 20s and 30s. They're presented with this very, you know, very serious disease where they might, you know, they might go into end-stage kidney disease, you know, and require dialysis or a transplant if they don't actually treat the disease. But, again, because they're asymptomatic otherwise, they really demand, they have a high bar for very safe and very convenient drugs, and I think that's where we can really kind of come in. And that's why I think just adding BAF into the equation, And even if, you know, even if the risk is. Over the longer term, it's kind of like, why would you do that if it's not in exchange for anything on the efficacy side, which, again, we haven't seen so far.

Alex Thomas Analyst — Stiefel

Yep. So maybe before we get to your phase one data, maybe we could talk a little about, too, you know, what the commercial landscape looks like. I mean, SuperPenMap's coming out a little less, almost a year on the market. TrueTalkNet was just approved over the summer. What do those launches look like, and what does that tell you also about where unmet need is?

Yeah, I think it speaks to the size of the market. I think, as I mentioned earlier, we estimate that this is a $20 billion market in the U.S. alone. You don't really need to squint to get there. I think, you know, a lot of companies have been talking about this, but if you just look at, you know, even if you take, you know, a typical haircut on gross-to-nets, I mean, these drugs have launched with wax in the $400 to $425K range, so it takes some, you know, some discount for net pricing. The eligible patients in the U.S. is something like $100,000, which would be the patients that, per the KDEO guidelines, are above 0.5 grams per day in proteinuria because there's about 170,000 to 200,000 total IGAM patients in the U.S. It's a very large market, and if you look at, like, patient start forms, we're in the low thousands still, right, if you look at the combination of Otsuka, PS, patient start forms, and then TrueTacna. If you go back and look at consensus peak sales for SIDBIT-PROMAT back in December, I think it was under $100 million for 2026, And it's on its way to doing something like $400 million. And so, again, that's only on a couple thousand patients. So I think that speaks right there to the amount of white space in the market. I think our prediction going forward, I think the monthlies should have an edge. We kind of mentioned convenience being a key factor. However, Vera has a very effective drug, and I think they'll also get some share. But we think that the B-cell modulators are really here to stay in front line. Like the KDEO guidelines say, on one hand, treat this like an autoimmune disease. And on another hand, you know, treat the local nephron loss. And so we think that patients with proteinuria above 0.5 grams per day are going to get an ACNR. They have some local nephron protection. You see some reduction of proteinuria. But they'll also, in combination, get a B cell modulator, which again, have been shown, as we've talked about, to be very safe and very effective.

Alex Thomas Analyst — Stiefel

So, man, let's walk through your phase one data. And maybe, you know, the key takeaways there around, you know, the confidence that potency matters and that your half-life extension is going to get you to a competitive dosing profile in IGAN.

Yeah, so you're exactly right. So the phase one was a single ascending dose study, really with the goal of informing what doses would look like at later stages of development. I think one thing that's especially attractive about IGAN from a development perspective is IGA lowering is very tightly correlated to UPCR reduction and EGFR stabilization, so it's much more informative compared to some other immunology. And it allows you to really do rigorous dose selection based on those phase one results. So, again, just to mention what you were talking about, we saw at the 700 milligram dose level a reduction in IgA around 70 percent, which is higher than had been seen by our competitors previous to that, and it speaks to the femtomolar binding affinity that Brad called on earlier. Here we also saw... Evidence of half-life extension that gives us a lot of confidence about being able to dose every 12 weeks. And so both of those who have informed our strategy and our dosing interval for our ongoing phase 2 study and our phase 3 study, which we've announced will initiate this quarter.

Alex Thomas Analyst — Stiefel

So, yeah, maybe let's walk through the phase two design. Why run an open-label phase two study, and why include both the every eight-week and 12-week dose, if you're so confident in the 12-week dosing paradigm?

Yeah, so I think the phase two serves... It serves a couple purposes. I think it's important, first of all, to be generating data in a competitive environment like this. That study initiated back in May, and we've said we'll be reporting out results in the second quarter of 2027, and that does an added benefit on Brad's side of the equation for investors like you, but for the phase three that we're And again, show those IGA reductions, show those UPCR reductions that will allow us to even more efficiently conduct this phase three trial. With regards to the two-dose levels, that's really from a global regulatory strategy. There is often a desire to see some degree of dose ranging, and so we want to be able to satisfy. Those requests up front, so we can move as efficiently as possible, and bring this drug to the patients who need it.

Alex Thomas Analyst — Stiefel

So, when we get the data next year, can you give us a sense of what kind of follow-up we should expect, how many patients, and is there a possibility that in a trial of this size, we'll start to see differentiation from this potency IgA reductions that you're seeing in phase one?

Yeah, so we're not giving the blow-by-blow operating updates, because otherwise, in every single investor meeting, we would be asked how enrollment is going. So we would just say, broadly, there's a lot of enthusiasm in the KOL community. We're running this trial at sites where there's a lot of knowledge about Jade 101 and a lot of excitement about Jade 101. So we initiated the trial in May. So if we announced data in Q2, you can kind of do the math for follow-up. So without getting into patient numbers, we would just say that we want to have a very good data set. I think typically you would want to see something like a six-month follow-up at a minimum. You've historically seen, you know, you can look at a, I think if you look at the old Alpine before Vertex acquired it, I think their initial trial readout was like six patients at week 36. So we plan to be, you know, a little bit more robust than that. We hope it obviously will have varying degrees of follow-up depending on, or varying degrees of patient numbers, depending on the level of follow-up. We won't have a very robust data set in the second quarter next year.

Alex Thomas Analyst — Stiefel

Do you think you'll be able to show differentiation at this stage?

Yeah, so it's a small study, so I think, you know, it's obviously challenging, right, because there can be noise on these, you know, on these small patient studies. So I think it's kind of like a totality of data, right? You want to kind of see, as Ed was alluding to, you want to see good UPCR reductions, I would say, at a minimum consistent with what's been seen in the prior gen agents at that 2-12 week time point. But then we want to kind of look at that in tandem with, like, what's GDIGA doing? What's the kinetics of GDIGA doing in terms of how quickly are we getting to, you know, the deep reductions and how, you know, how durable are they? So I think all of that will be answered. Obviously, there's a lot of questions around ADAs, too, so we're looking at ADAs in multiple doses. We know that Otsuka, in their phase three, they had 34% of patients had ADAs resulting in a reduction in exposure. And so we want to show that the design features of Jade 101 being fully human, you know, being selected as a novel epitope to not form these large molecular weight complexes that have been seen with SIDVIP from the map can really show a differentiation. They're very confident from the phase one results that we, you know, that we don't have a signal there, but obviously you want to see that continue to play out in the phase two as well.

Alex Thomas Analyst — Stiefel

So then, as you alluded to, you're planning to start your phase three this quarter, so pretty soon. There's obviously been a progression of phase three designs now in the IGAN space. Can you walk through kind of how we got to a one-year pivotal study from the classical two-year studies in the past?

Yeah, sure. So there was the NKF Consortium, National Kidney Foundation Consortium, And this was a gathering of health authorities, academia, as well as... Industry, and it was really looking at newer design options for these IgA nephropathy studies, particularly when you have these April and April-Bath combinations, given the data that's been seen to date, because really the question they were trying to solve for was you can't have patients. Beyond placebo therapy for two years, they're losing too much kidney function, so you're doing them a huge disservice by keeping that traditional study design. So they actually looked at a variety of different study design options, and where they landed was our study design for Phase III, which is one year of randomized placebo-controlled study, followed by 48 weeks, of an open-label component where those patients who were on placebo then receive active drug. I think the features of our study that we also find particularly attractive is that it's randomized two-to-one active versus placebo, again, carrying those same two-dose levels that we talked about in phase two. And so these patients have... A two-thirds likelihood of being on active therapy, but they also know that they're guaranteed to get on active therapy in that second open label period. And the other thing I would say is it wasn't just discussed at that meeting. Eliza Thompson, who's the director of the... Renal division of the FDA also talked about that at the GLOMCON meeting, which occurred later in the summer, reinforcing that study design as the new standard for these potent biologics targeting April and April Baff going forward.

Alex Thomas Analyst — Stiefel

Yep. So maybe the last question on IGAN, you know, obviously you're not the only company that... It's seeing the opportunity. And, again, beyond the first-gen bath Aprils, on the disease-modifying side, we have, you know, other next-gen Aprils. We have degraders of various flavors, and we have CD38s, among others. So, how do you see, you know, Jade, you know, fitting in in that future landscape?

Yeah, it's a good question. Yeah, I think we're obviously not the only company that sees the excitement commercially. We do think that, again, it matters. It kind of matters who went first here, too, right? So, again, just looking at Cibifrenumab as an example, right, that was the first B cell modulator that was approved. Really good clinical activity, good EGFR stabilization, very well tolerated, right? And so that has just created the bar to usurp that with another modality. I think very challenging. Without getting the specifics of the other modalities, I think, like, you know, there's infection risks in some. There's convenience challenges in others and sometimes in both. So, we think that the B-cell class is really here for frontline therapy to stay. So, obviously, our most direct competitor is Climb. They have Climb 116, which is a sweeping antibody. And they, you know, kudos to them. I mean, I think they recognize a similar unmet need that we also saw, and that convenience really matters for these patients. You want a selective anti-April, Cibipremlimap left, you know, left some efficacy on the table, given that it, you know, it underdosed from their phase two into their phase three. We have historically focused on potency really mattering, as we talked about earlier, and so that's why we think that we're able to get to those really deep IGA reductions. So we haven't quite seen that level from Climb, and they're a little bit behind. So we'll have to see more data, but it's a very large market with room for multiple players, and so very excited about what they're doing. It's great for patients, and it really, again, speaks to what a lot of KOLs talk about at all of these conferences, Which is just, convenience really matters for these patients, in addition to optimizing for clinical activity and safety.

Alex Thomas Analyst — Stiefel

Okay, so let's talk about 201, the BAF receptor mechanism, and sort of, maybe at a high level, how that is unique relative to when we talk about BAF April as a mechanism of action.

Yeah, good question. Yeah, so it's an afucosylated anti-BAF receptor, so there's really not many of them in development, which is, we actually kind of find a bit perplexing. Obviously Novartis is a very ambitious development program for their anti-BAF-R inalumab, so it's basically afucosylated for enhanced ADCC, so you can get really deep B-cell depletion, but by targeting the receptor, you don't require NK cells, so you can really get into tissues where a vector cell, such as NK cells, are sparse, and then BAF has this pro-survival signal, so when you deplete B-cells, you get this recovery of BAF as a compensatory response, and so you kind of block that from occurring, so that has the potential for Increased durability, and so from the ionalumab studies, we've seen kind of mixes of proof of mechanism slash proof of concept, depending on which indication you're talking about, but like we looked at the Sjogren's trial where they showed a positive result at their Q4 week dosing interval, but there were other things that were really encouraged, so they did, encouraged by, excuse me, so they did salivary gland biopsies and showed an 84% reduction in B cells in salivary glands, so that speaks to that tissue B cell depletion in certain diseases where that might, It might matter. It was also very well tolerated, right? And I think there's a lot of talk, you know, T-cell engagers have been generating a lot of interest. There's a lot of T-cell engagers in development, but you have to worry about things like cytokine release. You have to worry about some of the liver talks. And so we've seen with the Sjogren's trial, which is a very robust multiple phase three trial, basically there was safety that was consistent kind of across the board. And so I think the holy grail for something like a BAFAR It would be to get to, you know, something like T-cell engager, like B-cell depletion, but without any of the T-cell engager-like baggage. Ionilumab's main limitation is that it's got a relatively short human half-life of only 10 days, and so we were able to show in NHPs, broadly speaking, that we were able to retain the B-cell depletion, the ADCC activity, so let's bucket them into the so-called desirable features of Ionilumab while extending the half-life by a factor of two. And so going back to that Sjögren's trial, right, positive at Q4, they're probably getting pretty close to population-level BAF receptor occupancy at that Q4. They're clearly not getting that at Q12. So we think the receptor occupancy matters. And so when we pivot to our ongoing phase one in RA, right, again, I think that more of a surrogate healthy volunteer study. We're not ruling out RA developments, just probably not rising to the top of the list. We are going to be looking at that B cell depletion, not just the rate, you know, the level of B cell depletion, but that durability in tandem with the receptor occupancy, which we're also measuring through that study. So, really excited for that program, which, again, as I mentioned, has broad applicability in several of them.

Alex Thomas Analyst — Stiefel

Yeah, I guess, you know, with that phase one ongoing in RA, you know, data next year, you know, how are you thinking about indication selection strategy? You said RA might not be at the top of the list. Are you thinking about synergism with nephrology? Nephrology, are you thinking about white space opportunities relative to Ionalimab, how are you thinking about selecting indications moving forward?

Yeah, I mean, I think with as potent a B-cell depletor, both in the periphery and tissue, all of the above, but I think it's important, you know, looking at, we've looked at diseases like ankyo-associated vasculitis, I think is a very interesting disease and opportunity to get to look at tissue depletion there as well. I think seeing where ionolumab lands in ITP frontline, which should read out later this year, looking at things like membranous nephropathy, where obviously we have a very strong renal team, there's a whole host of things that we are contemplating as we're in the midst of this phase one study. I think, as we've stated, we recognize that there's potentially a huge pipeline in a product value of this. So we have been entertaining the notion of looking for partners because we do think it has such great potential. And then I think exactly as you pointed out, there's other renal conditions where the combination of 201, you know, even with an anti-April, could be very attractive as well.

Maybe I'll just linger on one thing. So obviously one thing we're monitoring is the Otsuka trial. So we've seen the Amgen. Actually, Amgen had more results in Sjogren's today. So I think there's a lot of enthusiasm with Sjogren's. We think Sjogren's is one of, you know, it's a very exciting commercial opportunity. But it's heterogeneous, the endpoints are complicated with the S-bree and the S-dye, et cetera. But we definitely have our eye on the CIVIT from the map study to see if April's adding anything in Sjogren's. And I think then we would think about a combination strategy for Sjogren's.

Alex Thomas Analyst — Stiefel

And that's expected to be out next year, right?

Yeah, yeah, I think the primary completion date is in March, if memory serves. So I would expect data in something like the second quarter.

Alex Thomas Analyst — Stiefel

Maybe, or ACR next year.

Yeah, yeah, exactly. So we'll see. Obviously, have our eye on that, but we're not making that investment ourselves, as everyone's alluding to.

Alex Thomas Analyst — Stiefel

Yeah, okay. So maybe let's talk in the last five minutes here or so about 301. You obviously presented some preclinical data here at EIDV a few, maybe a month or so ago now. So maybe can we walk through 301 and where that fits into the story?

Yeah, super excited about 301 as an anti-interferon beta, again, with a lot of the same components that we've talked about before with regards to potency as well as half-life extension, really in typical jade slash paragon fashion, looking at drugs that have best-in-class efficacy, but understanding how we can really improve and iterate upon those. So we're looking at the DASIK-HIBARTS, which is being developed by Pfizer. They had some very compelling Phase II data, both, and just to review dermatomyositis a little bit, it's, as the name implies, a disease of both the skin and the muscles. And they showed both very compelling data for CDASI, which is the skin metric component, and for the total improvement score, or TIS, they showed by point estimate very impressive results there as well. They currently have an ongoing phase two study, a phase three study, I should say, sorry. So we have announced that we're initiating our phase one in healthy volunteers. This quarter, again, it will be a single ascending dose study looking at PK. PD, because interferon beta in healthy individuals, the circulating levels are actually quite low. We're doing some exploratory biomarker measurements, but it will predominantly be a PK study which will inform our later stages of development.

Alex Thomas Analyst — Stiefel

Yep. So in terms of what you can see from a PK perspective in the phase one, sort of what level of de-risking should we think about here? Is this primarily like a trough coverage story? Is there significant PD biomarkers that we can look at? How should we think about that?

Yeah, it's really a trough coverage story, I would say. Again, because this is a disease of the skin and muscle, you need to be able to get into the muscle. And so we have informative data from Pfizer understanding what their dose levels look like. And in their phase two study, they actually used a different dose level, the 150 in their skin portion of their study, and a higher dose level of 600 for their muscle. And I think that speaks to the acknowledgement that for antibody therapies, you're getting into muscle at about 1% to 4% of the circulating range. So I think there's a lot of... And the utility from the Phase I study being able to target those trough levels even potentially exceed them to drive responses, again, in both the skin and the muscle. Yeah. And we showed preclinically higher binding affinity, greater potency. So, like, seeing if those manifest in a greater clinical activity, we would kind of view as upside. But if you're in the zip code of what Pfizer has shown from their Phase II, you have pretty clear path to best in disease, especially as Ed was alluded to on that critical skin component. And where we think that there's a very significant unmet need from those that are the one that's approved and those that are in development.

Alex Thomas Analyst — Stiefel

So how should we think about expansion more broadly into other type 1 interferon-driven diseases?

Yes, I mean, there's obviously diseases like the cutaneous lupuses of the world. I would say we're focused on DM, and especially I think one of the key challenges for the Pfizer study is that they were enrolling more than just DM, and that actually creates a screening issue, and we think that's one of the reasons why that trial's been moving relatively slow among others. But I think a pure DM is the initial approach, and then indication expansion, we are definitely thinking about, but we're going to get through the phase one results and then report more on that at a later time point.

Alex Thomas Analyst — Stiefel

Great. Brad, any final thoughts?

I don't think so. I think we covered everything. Thanks, as always, for having us.

Alex Thomas Analyst — Stiefel

Really appreciate it.

Yeah, awesome. Thanks, everyone. Thank you.

Alex Thomas Analyst — Stiefel

Yeah, thank you.

Analyst Q&A · 1 question
Full-screen source Call document